异基因造血干细胞移植后有巨细胞病毒感染风险的受者延长来特莫韦预防疗程的疗效与安全性:一项多中心、随机、双盲、安慰剂对照的3期试验
这项多中心随机双盲安慰剂对照3期试验纳入220例异基因造血干细胞移植后已接受来特莫韦预防至100天且仍有迟发性临床显著巨细胞病毒感染风险的CMV血清阳性受者,按2:1随机接受额外100天来特莫韦(总200天)或安慰剂。随机化至第28周(移植后200天),来特莫韦组临床显著CMV感染4/144(3%),安慰剂组14/74(19%),治疗差异-16.1%(95%CI -25.8至-6.5;p=0.0005)。
要点
- 移植后200天来特莫韦组临床显著CMV感染3%,安慰剂组19%,治疗差异-16.1%(95%CI -25.8至-6.5;p=0.0005)。
- 来特莫韦组与安慰剂组最常见不良事件为移植物抗宿主病43例(30%)vs 23例(31%)、腹泻17例(12%)vs 9例(12%)。
- 研究者未认为任何死亡与药物相关。
核心结论
- 异基因造血干细胞移植后将来特莫韦预防延长至200天可有效且安全地降低有风险患者迟发性临床显著巨细胞病毒感染的发生率。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照3期试验,在六个国家(法国、德国、意大利、日本、英国和美国)的32个中心开展。
- 纳入年龄≥18岁、CMV血清阳性、已接受来特莫韦预防至移植后100天且仍存在迟发性临床显著CMV感染高风险(无既往临床显著CMV感染史)的造血干细胞移植受者。
- 按2:1随机分配接受额外100天来特莫韦(总200天;来特莫韦组)或100天安慰剂(总100天来特莫韦;安慰剂组),按研究中心和单倍体供者(是或否)分层。
- 来特莫韦剂量为口服或静脉480 mg每日一次,使用环孢素A者调整为240 mg每日一次。
- 2019年6月21日至2022年3月16日筛选255例,220例(86%)被随机分配(来特莫韦组145例[66%],安慰剂组75例[34%])。
主要发现
- 随机化至第28周(移植后200天),来特莫韦组144例中4例(3%)发生临床显著CMV感染,安慰剂组74例中14例(19%)发生,治疗差异-16.1%(95%CI -25.8至-6.5;p=0.0005)。
- 来特莫韦组与安慰剂组最常见不良事件:移植物抗宿主病43例(30%)vs 23例(31%),腹泻17例(12%)vs 9例(12%),恶心16例(11%)vs 13例(18%),发热13例(9%)vs 9例(12%),食欲下降6例(4%)vs 9例(12%)。
- 最常报告的严重不良事件为复发性急性髓系白血病6例(4%)vs 无,以及肺炎3例(2%)vs 2例(3%)。
- 研究者未认为任何死亡与药物相关。
关键数值与推荐
- 主要疗效终点为随机化至第28周(移植后200天)发生临床显著CMV感染的受者比例,采用全分析集(至少接受一剂研究干预者)分析。
- 安全性在所有按实际接受治疗分析的受者中评估(即根据所分配研究干预至少接受一剂者)。
临床怎么用
- 原文结论认为,对于有风险的患者,将来特莫韦预防延长至造血干细胞移植后200天可有效且安全地降低迟发性临床显著CMV感染的发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a pivotal phase 3 trial of cytomegalovirus prophylaxis with letermovir for up to 100 days after allogeneic haematopoietic stem-cell transplantation (HSCT), 12% of participants developed clinically significant cytomegalovirus infection after letermovir was discontinued. We aimed to evaluate the efficacy and safety of extending the duration of letermovir prophylaxis for clinically significant cytomegalovirus infection from 100 days to 200 days following HSCT. METHODS: We conducted a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 32 sites in six countries (France, Germany, Italy, Japan, the UK, and the USA). Cytomegalovirus‑seropositive HSCT recipients (aged ≥18 years) who had received letermovir prophylaxis for up to 100 days following HSCT and who remained at high risk of late clinically significant cytomegalovirus infection (with no previous history of clinically significant cytomegalovirus infection, defined as initiation of pre-emptive therapy for documented cytomegalovirus viraemia, onset of cytomegalovirus end-organ disease, or both) were eligible. Participants were randomly assigned (2:1) to receive either an additional 100 days (ie, a total of 200 days; letermovir group) of oral or intravenous letermovir 480 mg once daily, adjusted to 240 mg once daily for participants on cyclosporin A, or 100 days of a placebo comparator for letermovir (ie, a total of 100 days of letermovir; placebo group), following HSCT. Randomisation was done using a central interactive response technology system, stratified by study centre and haploidentical donor (yes or no). Participants, investigators, and sponsor personnel were masked to the treatment allocation. The primary efficacy endpoint was the proportion of participants from randomisation to week 28 (200 days after HSCT) with clinically significant cytomegalovirus infection, analysed using the full analysis set population (ie, those who received at least one dose of study intervention). Safety was analysed in all participants as treated (ie, those who received at least one dose according to the study intervention they were assigned to). This study is registered with ClinicalTrials.gov, NCT03930615, and is complete. FINDINGS: Between June 21, 2019, and March 16, 2022, 255 patients were screened for eligibility and 220 (86%) were randomly assigned (145 [66%] in the letermovir group and 75 [34%] in the placebo group). Between randomisation and week 28, four (3%) of 144 participants in the letermovir group and 14 (19%) of 74 in the placebo group developed clinically significant cytomegalovirus infection (treatment difference -16·1% [95% CI -25·8 to -6·5]; p=0·0005). The most common adverse events among participants in the letermovir group versus the placebo group were graft-versus-host disease (43 [30%] vs 23 [31%]), diarrhoea (17 [12%] vs nine [12%]), nausea (16 [11%] vs 13 [18%]), pyrexia (13 [9%] vs nine [12%]), and decreased appetite (six [4%] vs nine [12%]). The most frequently reported serious adverse events were recurrent acute myeloid leukaemia (six [4%] vs none) and pneumonia (three [2%] vs two [3%]). No deaths were considered to be drug-related by the investigator. INTERPRETATION: Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk. FUNDING: Merck Sharp & Dohme LLC.
引用
- Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2023. PMID: 38142695. doi:10.1016/S2352-3026(23)00344-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。